ArticleBMC pregnancy and childbirth2026
Live births after low initial β-hCG in IVF cycles: a retrospective cohort study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum beta-human chorionic gonadotropin (β-hCG) hormone is a well-established biomarker used for pregnancy monitoring and prognosis in in vitro fertilization (IVF) cycles. After embryo transfer, a high serum β-hCG level with a prompt doubling time is typically reassuring, while a low initial β-hCG often leads to counselling around likely impending pregnancy loss and/or ectopic pregnancy. However, the number of patients with low β-hCG who ultimately deliver a live birth is unclear.
methodsThis is a single-centre retrospective cohort study of IVF pregnancies between January 2019 and December 2022. Serum β-hCG was drawn 14 days post-fertilization. We considered an initial β-hCG ≤ 50 mIU/mL as low. A logistic mixed-effects regression model assessed the odds of live birth for every 10 mIU/mL increase in β-hCG, adjusting for patient and cycle characteristics (age, body mass index, embryo stage, number of embryos transferred, and preimplantation genetic testing for aneuploidy). Receiver operating characteristic curves were plotted to determine optimal cut-points.
resultsAmong 2443 pregnancies, the prevalence of live birth was 12% for those with an initial β-hCG ≤ 50 mIU/mL. For each 10 mIU/mL difference in initial β-hCG, the odds of live birth increased significantly (aOR = 1.035 [95% CI 1.027, 1.042]). Receiver operating characteristic curve analysis showed that an initial β-hCG greater than 22.5 mIU/mL identified over 99% of patients who ultimately had a live birth (sensitivity 1, specificity 0.21, AUC 0.726). The rate of change from initial β-hCG demonstrated stronger discriminatory performance for live birth among patients with low initial β-hCG (AUC 0.876 [95% CI 0.84, 0.91]) than among those with an initial β-hCG > 50 mIU/mL (AUC 0.584 [95% CI 0.56, 0.61]).
conclusionsWhile IVF pregnancies with a low initial β-hCG can result in live birth, the likelihood is low. The rate of β-hCG rise emerged as a stronger discriminator of pregnancy outcomes when the initial β-hCG is low. Live birth was extremely rare when the initial β-hCG was below 22.5 mIU/mL. These findings offer prognostic data to guide counselling and refine expectations after IVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.